TNDMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

TANDEM DIABETES CARE INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$16.38+0.14 (+0.86%)

Close on Oct 19, 2026

Market cap: $1.13B
P/E (TTM): –
Dividend yield: –

TANDEM DIABETES CARE INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Revenue	1,015	940	748	801	703	499	362	184	108	84	73	50	29	2.48
Cost of Revenue	469	451	380	388	327	238	168	94	64	61	46	34	23	3.82
Gross Profit	546	490	368	413	376	261	194	90	44	24	27	15	6.17	-1.35
Research & Development	193	199	170	139	92	64	45	29	21	19	17	16	11	9.01
Selling, General & Admin	445	390	353	336	262	205	166	105	86	83	79	75	45	23
Advertising Expenses	–	–	–	–	–	–	0.90	0.90	1.10	0.90	1.00	1.50	0.70	0.07
Operating Expenses	733	589	601	506	354	268	211	134	107	102	96	91	56	32
Operating Income	-187	-99	-233	-93	23	-7.96	-17	-45	-63	-78	-69	-76	-49	-33
Interest Expense	7.91	7.42	9.88	6.21	–	–	–	–	–	–	–	–	–	–
Income from Equity Investments	-14	-2.05	0	0	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-13	7.26	13	0.00	-6.75	-28	-7.88	-78	-10	-5.41	-3.40	-3.79	-14	0.03
Asset Impairment Charges	0	0	0	0	0	–	–	–	–	–	–	–	–	–
Legal Settlements	-20	0	0	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-200	-92	-220	-93	16	-36	-25	-123	-73	-83	-72	-79	-63	-33
Income Tax Expense	4.44	4.16	2.36	1.74	0.34	-1.90	0.15	0.05	0.01	-0.02	0.01	0.07	–	–
Net Income incl. Noncontrolling Interests	-205	-96	-223	-95	16	-34	-25	-123	-73	-83	–	–	–	–
Net Income	-205	-96	-223	-95	16	-34	-25	-123	-73	-83	-72	-80	-63	-33
Net Income to Common	–	–	-223	-95	16	-34	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-3.04	-1.47	-3.43	-1.47	0.25	-0.56	-0.42	-2.55	-12.87	-27.30	-25.04	-34.20	-214.60	-1,758.80
EPS (Diluted)(per share)	-3.04	-1.47	-3.43	-1.47	0.24	-0.56	-0.42	-2.55	-12.87	-27.30	-25.04	-34.20	-214.60	-1,758.80
Shares Outstanding (Basic, Weighted)(shares)	67	65	65	64	63	61	59	48	5.68	3.06	2.89	2.33	0.29	0.02
Shares Outstanding (Diluted, Weighted)(shares)	67	65	65	64	64	61	59	48	5.68	3.06	2.89	2.33	0.29	0.02
EBITDA	-170	-83	-218	-79	36	2.49	-11	-39	-56	-73	-64	-71	-46	-31

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 56.0%
Operating margin: -4.4%
Net margin: -6.1%
Return on equity, FY2025: -97.9%

Financial strength

Current ratio: 3.18
Debt to equity: 4.62
Debt to assets: 52.2%
Cash to current liabilities: 24.8%

Valuation

P/E ratio: –
Price to sales: 1.09
Price to book: 8.67
Dividend yield: –